Sartorius Stedim Biotech (SSB), a supplier to the pharma and biotech industries, has acquired Cellca GmbH, a contract services company provided biologic-based process-development services, based in Laupheim, Germany. Founded in 2005, the company with around 30 employees generated sales revenue of approximately EUR 6 million ($6.6 million) in 2014.

Cellca's major customers are biopharmaceutical companies as well as biosimilar firms that do not or only partly conduct their process development in their in-house facilities. Through this acquisition, Sartorius Stedim Biotech is further expanding its service offering for process development. SSB has made two recent acquisitions in this area: BioOutsource and TAP Biosystems.

Source: Sartorius Stedim Biotech